Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that its Chief Medical Officer, Michael Caligiuri, MD, will be presenting at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy. The event will feature Jeffrey Miller, M.D. (University of Minnesota) and Michael Caligiuri, M.D. (City of Hope National Medical Center) who will discuss CytoImmune’s approach for human natural killer (NK) cell immunotherapy with a heavy focus on programmed death-ligand 1 (PD-L1)+ NK cell for use in treating lung cancer, and fms-like tyrosine kinase 3 (FLT3) CAR NK cell therapy for use in treating Acute Myeloid Leukemia (AML). A live Q&A session will follow the formal presentations.
Register here: https://lifesci.events/CytoImmune